Literature DB >> 19399801

Hepatitis B virus DNA levels and outcomes in chronic hepatitis B.

Chien-Jen Chen1, Hwai-I Yang, Uchenna H Iloeje.   

Abstract

Serum hepatitis B virus (HBV) DNA levels can fluctuate markedly during the course of chronic HBV infection. Both case-control and cohort studies have shown a significant, dose-response association between serum HBV DNA levels measured at the time of initial evaluation and the subsequent risk of cirrhosis. A similar direct relationship has been shown for the risk of hepatocellular carcinoma (HCC) in cross-sectional, case-control, and cohort studies. Interventional studies have shown a strong correlation between the indices of disease activity seen on liver biopsy and levels of serum HBV DNA. These studies have also shown that reduction in HBV DNA levels correlate strongly with improvements in liver histology. For patients with HCC, prognosis (including risk of death, metastasis, and recurrence following surgery) is worse with higher serum HBV DNA levels. The preponderance of the evidence in the published literature demonstrates that serum HBV DNA level is an important and independent risk factor for disease progression in chronic hepatitis B. The relative importance of serial HBV DNA measurements, the loss of hepatitis B e and surface antigens, as well as the emergence of HBV mutants in the progression of chronic hepatitis B, especially in young patients, is an important need for future research.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19399801     DOI: 10.1002/hep.22884

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  101 in total

Review 1.  Epidemiology of viral hepatitis and hepatocellular carcinoma.

Authors:  Hashem B El-Serag
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

Review 2.  New virologic tools for management of chronic hepatitis B and C.

Authors:  Stéphane Chevaliez; Christophe Rodriguez; Jean-Michel Pawlotsky
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

3.  Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China.

Authors:  Weixia Ke; Chi Zhang; Li Liu; Yanhui Gao; Zhenjiang Yao; Xiaohua Ye; Shudong Zhou; Yi Yang
Journal:  Hepatol Int       Date:  2016-06-07       Impact factor: 6.047

Review 4.  Global Epidemiology of Hepatocellular Carcinoma (HCC Epidemiology).

Authors:  Aysegul Ozakyol
Journal:  J Gastrointest Cancer       Date:  2017-09

5.  Hepatocellular carcinoma risk scores: ready to use in 2015?

Authors:  Chien-Jen Chen; Mei-Hsuan Lee; Jessica Liu; Hwai-I Yang
Journal:  Hepat Oncol       Date:  2015-01-12

6.  Cost-Effectiveness Comparison Between the Response-Guided Therapies and Monotherapies of Nucleos(t)ide Analogues for Chronic Hepatitis B Patients in China.

Authors:  Keng Lai; Chi Zhang; Weixia Ke; Yanhui Gao; Shudong Zhou; Li Liu; Yi Yang
Journal:  Clin Drug Investig       Date:  2017-03       Impact factor: 2.859

7.  Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance.

Authors:  C Sarrecchia; V Svicher; A Volpi; R Salpini; L Ceccarelli; P Sordillo; A Bertoli; C F Perno; M Andreoni
Journal:  Infection       Date:  2011-06-15       Impact factor: 3.553

Review 8.  Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead.

Authors:  Heiner Wedemeyer; Michael P Manns
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-01       Impact factor: 46.802

Review 9.  Does antiviral therapy reduce complications of cirrhosis?

Authors:  Goh Eun Chung; Jeong-Hoon Lee; Yoon Jun Kim
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 10.  Association between metabolic factors and chronic hepatitis B virus infection.

Authors:  Chien-Hsieh Chiang; Kuo-Chin Huang
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.